Larger-scale studies with balanced representation of different PitNET subtypes are essential to confirm these findings and to better define the prognostic and therapeutic relevance of PD-L1, cyclin D1, P53, and Ki-67 expression in pituitary tumors. This evidence concerns the gene TP53 and pituitary tumor.